Up next

Autoplay

The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma

2 Views • 07/18/23
Share
Embed
administrator
administrator
Subscribers
0

Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay